EMA/CHMP updates on recent reviews of three classes of meds

28 March 2020

Following the March 23-26 meetings of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), outcomes of reviews on three groups of medicines have been announced. These are as follows:

Outcome of review on direct oral anticoagulants

No change to the conditions of use of the direct oral anticoagulants Eliquis (apixaban), from New York-based pharma majors Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE), Pradaxa (dabigatran etexilate), from Germany’s Boehringer Ingelheim, and Xarelto (rivaroxaban), from German major Bayer (BAYN: D) is needed following a review of the results of a European study of real-world data for these medicines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK